Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period

Author： Correia Christopher   Walsh Sharon   Bigelow George   Strain Eric  

Publisher： Springer Publishing Company

ISSN： 0033-3158

Source： Psychopharmacology, Vol.189, Iss.3, 2006-12, pp. : 297-306

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Buprenorphine/naloxone reduces drug abuse, costs

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 552, 2008-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Spotlight on Buprenorphine/Naloxone in the Treatment of Opioid Dependence†

By Orman Jennifer S.   Keating Gillian M.  

CNS Drugs, Vol. 23, Iss. 10, 2009-10 ,pp. : 899-902

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment

By Douglas Bruce R.  

The American Journal of Drug and Alcohol Abuse, Vol. 39, Iss. 2, 2013-03 ,pp. : 80-85

Informa Healthcare

Access to resources Recommend Favorite

Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International Review

By  

Current Drug Abuse Reviews, Vol. 4, Iss. 1, 2011-03 ,pp. : 28-41

Bentham Science Publishers

Access to resources Recommend Favorite

A randomized, 14-day, double-blind study evaluating conversion from hydrocodone/acetaminophen (Vicodin) to buprenorphine transdermal system 10 μg/h or 20 μg/h in patients with osteoarthritis pain

By Ripa Steven R   McCarberg Bill H   Munera Catherine   Wen Warren   Landau Craig J  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. : 1229-1241

Informa Healthcare

Access to resources Recommend Favorite